pepdex
← Back to index
№ 022

Cagrilintide

Long-acting amylin agonist. Different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.

Fat Loss
Evidence: Moderate
Half-life
~7 days
Route
Subcutaneous
Cycle
Open-ended
Schedule
Once weekly
In plain English

Cagrilintide is an amylin agonist — a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational. Phase 3 trials by Novo Nordisk, often paired with semaglutide as 'CagriSema'.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Not yet approved. Trial access only.

Who it's for

  • →Users plateaued on Semaglutide or Tirzepatide
  • →People wanting cleaner satiety without bigger GLP-1 nausea
  • →Combination-therapy stacks under provider guidance

What to expect

  1. Week 1

    Mild appetite drop. Less nausea than the GLP-1 drugs.

  2. Week 4

    First titration step. Modest weight loss alone, stronger when stacked with semaglutide.

  3. Week 8

    Steady-state. Best results in 'CagriSema' combination with semaglutide.

Dosing protocol

Start 0.3 mg sub-q weekly. Titrate to 2.4 mg over 4-week steps. Common max 2.4 mg.

Stacks well with

Semaglutide (the canonical 'CagriSema' combination)
Standalone for amylin-only effect

Side effects

01Mild nausea
02Reduced appetite
03Constipation
04Fatigue

When NOT to use

  • ⚠History of medullary thyroid carcinoma or MEN-2
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • A1C if metabolic context
  • • Lipid panel

Common mistakes

  • • Expecting standalone results to match Tirzepatide (it won't)
  • • Titrating too fast
  • • Skipping protein during the cut

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Cagrilintide?+
Cagrilintide is an amylin agonist — a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.
Is Cagrilintide FDA approved?+
Investigational. Phase 3 trials by Novo Nordisk, often paired with semaglutide as 'CagriSema'.
Is Cagrilintide banned by WADA?+
Cagrilintide is not currently on the WADA prohibited list.
Are you still natty after taking Cagrilintide?+
No. Cagrilintide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Cagrilintide?+
Not yet approved. Trial access only.
What's the typical dose of Cagrilintide?+
Start 0.3 mg sub-q weekly. Titrate to 2.4 mg over 4-week steps. Common max 2.4 mg.
What are the side effects of Cagrilintide?+
Common side effects include: Mild nausea; Reduced appetite; Constipation; Fatigue. Less common effects and full safety details are on the entry page.
How long until Cagrilintide starts working?+
Mild appetite drop. Less nausea than the GLP-1 drugs.